![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
EFFECT OF FALDAPREVIR ON ATAZANAVIR PHARMACOKINETICS IN PATIENTS WITH HIV/HCV CO-INFECTION
|
|
|
Reported by Jules Levin
CROI 2014 March 3-6 Boston, MA
Mark Nelson1, Keikawus Arasteh2, Mamta K Jain3, Vicente Soriano4, Jose Valdez Madruga5, Juvencio Furtado6, Manuel Battegay7, Fenglei Huang8, Montserrat Manero9, Douglas Dieterich10
1Chelsea and Westminster Hospital, London, UK; 2EPIMED/Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany; 3UT Southwestern Medical Center, Dallas, TX, US; 4Hospital Carlos III, Madrid, Spain; 5Centro de Referencia e Treinamento DST/AIDS, Sao Paulo, Brazil; 6Faculdade de Medicina do ABC and Hospital Heliopolis, Sao Paulo, Brazil; 7University Hospital Basel, Basel, Switzerland; 8Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA; 9Boehringer Ingelheim Espana, S.A., Barcelona, Spain; 10Mount Sinai Medical Center, New York, NY, USA
![CROI1.gif](../images/032114/032114-5/CROI1.gif)
![CROI2.gif](../images/032114/032114-5/CROI2.gif)
![CROI3.gif](../images/032114/032114-5/CROI3.gif)
![CROI4.gif](../images/032114/032114-5/CROI4.gif)
![CROI5.gif](../images/032114/032114-5/CROI5.gif)
![CROI6.gif](../images/032114/032114-5/CROI6.gif)
![CROI7.gif](../images/032114/032114-5/CROI7.gif)
![CROI8.gif](../images/032114/032114-5/CROI8.gif)
![CROI9.gif](../images/032114/032114-5/CROI9.gif)
![CROI10.gif](../images/032114/032114-5/CROI10.gif)
![CROI11.gif](../images/032114/032114-5/CROI11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|